Replies to post #29124 on Relief Therapeutics Holding AG (RLFTF)

[elllk]

Look back for posts earlier today which very nicely explain the difference between PhaseBio's VIP and RLF100 VIP.

[Demogod]

Apparently related to different VIP receptors VPAC1 and VPAC2. PhaseBio's targeted VPAC2 (and RLF targets VPAC1).

https://pubchem.ncbi.nlm.nih.gov/substance/135651911

Difference between VPAC1&2:

https://en.m.wikipedia.org/wiki/Vasoactive_intestinal_peptide_receptor

Sorry if old news here.

...So lack of results for PhaseBio really has no bearing on possible results with Relief's efforts.